JPWO2021153984A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021153984A5 JPWO2021153984A5 JP2022546665A JP2022546665A JPWO2021153984A5 JP WO2021153984 A5 JPWO2021153984 A5 JP WO2021153984A5 JP 2022546665 A JP2022546665 A JP 2022546665A JP 2022546665 A JP2022546665 A JP 2022546665A JP WO2021153984 A5 JPWO2021153984 A5 JP WO2021153984A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- cancer
- groups
- antibody
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 14
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 239000000611 antibody drug conjugate Substances 0.000 claims 10
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 9
- -1 benzoselenophene compound Chemical class 0.000 claims 9
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 9
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 239000000126 substance Substances 0.000 claims 6
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 230000002062 proliferating effect Effects 0.000 claims 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 3
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims 3
- 125000002252 acyl group Chemical group 0.000 claims 3
- 125000004442 acylamino group Chemical group 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 3
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 claims 3
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims 3
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 3
- 125000004691 alkyl thio carbonyl group Chemical group 0.000 claims 3
- 125000004414 alkyl thio group Chemical group 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 125000003277 amino group Chemical group 0.000 claims 3
- 125000005199 aryl carbonyloxy group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000002910 aryl thiol group Chemical group 0.000 claims 3
- 125000005200 aryloxy carbonyloxy group Chemical group 0.000 claims 3
- 125000004104 aryloxy group Chemical group 0.000 claims 3
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 3
- 229910052794 bromium Inorganic materials 0.000 claims 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 150000007942 carboxylates Chemical group 0.000 claims 3
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- 239000000460 chlorine Substances 0.000 claims 3
- 229940126214 compound 3 Drugs 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 239000011737 fluorine Substances 0.000 claims 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 3
- 125000000524 functional group Chemical group 0.000 claims 3
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 150000002367 halogens Chemical group 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 3
- 125000002346 iodo group Chemical group I* 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000004043 oxo group Chemical group O=* 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 3
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical group [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 claims 3
- 125000004193 piperazinyl group Chemical group 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 3
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 3
- 125000000565 sulfonamide group Chemical group 0.000 claims 3
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 claims 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 208000020084 Bone disease Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 2
- 206010057644 Testis cancer Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 206010046798 Uterine leiomyoma Diseases 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 208000035269 cancer or benign tumor Diseases 0.000 claims 2
- 229950007296 cantuzumab mertansine Drugs 0.000 claims 2
- 208000024558 digestive system cancer Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 229950009760 epratuzumab Drugs 0.000 claims 2
- 230000000893 fibroproliferative effect Effects 0.000 claims 2
- 201000010231 gastrointestinal system cancer Diseases 0.000 claims 2
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 229960001001 ibritumomab tiuxetan Drugs 0.000 claims 2
- 201000002313 intestinal cancer Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000010260 leiomyoma Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 206010027191 meningioma Diseases 0.000 claims 2
- 208000037819 metastatic cancer Diseases 0.000 claims 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 229950001072 tadocizumab Drugs 0.000 claims 2
- 201000003120 testicular cancer Diseases 0.000 claims 2
- 229960003989 tocilizumab Drugs 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 208000010579 uterine corpus leiomyoma Diseases 0.000 claims 2
- 201000007954 uterine fibroid Diseases 0.000 claims 2
- BNRDGHFESOHOBF-UHFFFAOYSA-N 1-benzoselenophene Chemical compound C1=CC=C2[se]C=CC2=C1 BNRDGHFESOHOBF-UHFFFAOYSA-N 0.000 claims 1
- 229940126624 Tacatuzumab tetraxetan Drugs 0.000 claims 1
- 229960000548 alemtuzumab Drugs 0.000 claims 1
- 229940125644 antibody drug Drugs 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 229950003145 apolizumab Drugs 0.000 claims 1
- 229950002882 aselizumab Drugs 0.000 claims 1
- 229950001863 bapineuzumab Drugs 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 229960005522 bivatuzumab mertansine Drugs 0.000 claims 1
- 229950006754 cedelizumab Drugs 0.000 claims 1
- 229960003115 certolizumab pegol Drugs 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 229960002806 daclizumab Drugs 0.000 claims 1
- 229960002224 eculizumab Drugs 0.000 claims 1
- 229960000284 efalizumab Drugs 0.000 claims 1
- 229950004292 erlizumab Drugs 0.000 claims 1
- 229950008579 ertumaxomab Drugs 0.000 claims 1
- 229950001563 felvizumab Drugs 0.000 claims 1
- 229950004923 fontolizumab Drugs 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 229960000578 gemtuzumab Drugs 0.000 claims 1
- 229950004101 inotuzumab ozogamicin Drugs 0.000 claims 1
- 229960005386 ipilimumab Drugs 0.000 claims 1
- 229950000518 labetuzumab Drugs 0.000 claims 1
- 229950002950 lintuzumab Drugs 0.000 claims 1
- 229950008001 matuzumab Drugs 0.000 claims 1
- 229960005108 mepolizumab Drugs 0.000 claims 1
- 229960001521 motavizumab Drugs 0.000 claims 1
- 229960005027 natalizumab Drugs 0.000 claims 1
- 229950010203 nimotuzumab Drugs 0.000 claims 1
- 229950005751 ocrelizumab Drugs 0.000 claims 1
- 229960000470 omalizumab Drugs 0.000 claims 1
- 229960000402 palivizumab Drugs 0.000 claims 1
- 229960001972 panitumumab Drugs 0.000 claims 1
- 229950011485 pascolizumab Drugs 0.000 claims 1
- 229960002087 pertuzumab Drugs 0.000 claims 1
- 229950003203 pexelizumab Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229960003876 ranibizumab Drugs 0.000 claims 1
- 229960003254 reslizumab Drugs 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 229950009092 rovelizumab Drugs 0.000 claims 1
- 229950005374 ruplizumab Drugs 0.000 claims 1
- 229950008684 sibrotuzumab Drugs 0.000 claims 1
- 229950003804 siplizumab Drugs 0.000 claims 1
- 229950006551 sontuzumab Drugs 0.000 claims 1
- 229950004218 talizumab Drugs 0.000 claims 1
- 229950001788 tefibazumab Drugs 0.000 claims 1
- 229950001802 toralizumab Drugs 0.000 claims 1
- 229960005267 tositumomab Drugs 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 229950003364 tucotuzumab celmoleukin Drugs 0.000 claims 1
- 108700008509 tucotuzumab celmoleukin Proteins 0.000 claims 1
- 229950004362 urtoxazumab Drugs 0.000 claims 1
- 229950004393 visilizumab Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20200011222 | 2020-01-30 | ||
| KR10-2020-0011222 | 2020-01-30 | ||
| PCT/KR2021/001082 WO2021153984A1 (ko) | 2020-01-30 | 2021-01-27 | 벤조셀레노펜계 화합물, 이를 포함하는 약학적 조성물 및 항체-약물 결합체 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023514520A JP2023514520A (ja) | 2023-04-06 |
| JP2023514520A5 JP2023514520A5 (https=) | 2023-09-19 |
| JPWO2021153984A5 true JPWO2021153984A5 (https=) | 2023-09-19 |
| JP7504209B2 JP7504209B2 (ja) | 2024-06-21 |
Family
ID=77079632
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020155441A Active JP7726628B2 (ja) | 2020-01-30 | 2020-09-16 | ベンゾセレノフェン系化合物、これを含む薬学的組成物及び抗体－薬物複合体 |
| JP2022546665A Active JP7504209B2 (ja) | 2020-01-30 | 2021-01-27 | ベンゾセレノフェン系化合物、これを含む薬学的組成物及び抗体－薬物複合体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020155441A Active JP7726628B2 (ja) | 2020-01-30 | 2020-09-16 | ベンゾセレノフェン系化合物、これを含む薬学的組成物及び抗体－薬物複合体 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11576896B2 (https=) |
| EP (1) | EP4083041A4 (https=) |
| JP (2) | JP7726628B2 (https=) |
| KR (2) | KR102894542B1 (https=) |
| CN (1) | CN115038699B (https=) |
| AU (1) | AU2021212559B2 (https=) |
| CA (1) | CA3165524C (https=) |
| WO (1) | WO2021153984A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102894542B1 (ko) * | 2020-01-30 | 2025-12-03 | (주)에임드바이오 | 벤조셀레노펜계 화합물, 이를 포함하는 약학적 조성물 및 항체-약물 결합체 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| ES2244991T3 (es) | 1996-03-08 | 2005-12-16 | The Scripps Research Institute | Analogosmcbi de cc-1065 y las duocarmicinas. |
| BRPI0617546A2 (pt) * | 2005-09-26 | 2011-07-26 | Medarex Inc | conjugado de fÁrmaco-anticorpo, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula de tumor, mÉtodo para retardar ou interromper o crescimento de um tumor em um sujeito mamÍfero e composto |
| EP1994000B1 (en) * | 2006-02-02 | 2017-08-23 | Syntarga B.V. | Water-soluble cc-1065 analogs and their conjugates |
| AU2007211840B2 (en) * | 2006-02-03 | 2012-03-01 | Bionomics Limited | Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors |
| TWI412367B (zh) * | 2006-12-28 | 2013-10-21 | 梅達雷克斯有限責任公司 | 化學鏈接劑與可裂解基質以及其之綴合物 |
| KR101418776B1 (ko) * | 2011-09-28 | 2014-07-14 | 사회복지법인 삼성생명공익재단 | 셀레노펜-접합 방향족 화합물, 및 이의 제조 방법 |
| WO2013048177A2 (ko) * | 2011-09-28 | 2013-04-04 | 세종대학교산학협력단 | 셀레노펜-접합 방향족 화합물, 및 이의 제조 방법 |
| KR101460207B1 (ko) * | 2011-12-07 | 2014-11-11 | 세종대학교산학협력단 | 셀레노펜-접합 방향족 화합물을 포함하는 항암제 |
| US9819889B2 (en) * | 2015-08-07 | 2017-11-14 | Omnivision Technologies, Inc. | Method and system to implement a stacked chip high dynamic range image sensor |
| KR101775440B1 (ko) * | 2015-10-07 | 2017-09-06 | 세종대학교산학협력단 | 벤조셀레노펜계 화합물 및 이를 포함하는 항체-약물 결합체 |
| KR102894542B1 (ko) * | 2020-01-30 | 2025-12-03 | (주)에임드바이오 | 벤조셀레노펜계 화합물, 이를 포함하는 약학적 조성물 및 항체-약물 결합체 |
-
2020
- 2020-09-16 KR KR1020200118786A patent/KR102894542B1/ko active Active
- 2020-09-16 JP JP2020155441A patent/JP7726628B2/ja active Active
-
2021
- 2021-01-27 KR KR1020210011551A patent/KR102596247B1/ko active Active
- 2021-01-27 CN CN202180012034.0A patent/CN115038699B/zh active Active
- 2021-01-27 WO PCT/KR2021/001082 patent/WO2021153984A1/ko not_active Ceased
- 2021-01-27 EP EP21748317.1A patent/EP4083041A4/en active Pending
- 2021-01-27 CA CA3165524A patent/CA3165524C/en active Active
- 2021-01-27 JP JP2022546665A patent/JP7504209B2/ja active Active
- 2021-01-27 AU AU2021212559A patent/AU2021212559B2/en active Active
- 2021-01-29 US US17/161,771 patent/US11576896B2/en active Active
-
2022
- 2022-07-29 US US17/815,958 patent/US11938115B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2545977T3 (es) | Combinaciones de un conjugado de anticuerpo-fármaco anti-HER2 y agentes quimioterapéuticos, y métodos de uso | |
| US8394795B2 (en) | Pyrazole [3, 4-B] pyridine Raf inhibitors | |
| EP2265609B1 (en) | Imdizo [4. 5-b] pyridine derivatives used as raf inhibitors | |
| AU2013255613B2 (en) | Pyrrolobenzodiazepines | |
| JP2013091670A5 (https=) | ||
| JPWO2021153984A5 (https=) | ||
| US8338452B2 (en) | Raf inhibitor compounds and methods of use thereof | |
| EP1857446B1 (en) | Derivatives of 3-(2,4-dihydroxyphenyl)-1,2,4-triazole useful in the treatment of cancer | |
| RU2012155606A (ru) | Гидроксилированные и метоксилированные циклопента[d]пиримидины в качестве ингибиторов акт протеинкиназ | |
| CA2771893A1 (en) | Raf inhibitor compounds and methods of use thereof | |
| US11576896B2 (en) | Benzoselenophene-based compounds, pharmaceutical compositions and antibody-drug conjugates including the same | |
| Harish et al. | Studies on the catalytic activity of mesoporous alumina-aluminophosphate (Al2O3–AlPO4) materials in the synthesis of N, N′-diphenyl urea | |
| AU2024204988A1 (en) | Combinations of an anti-HER2 antibody-drug conjugate and chemotherapeutic agents, and methods of use | |
| US20180282324A1 (en) | Crystalline forms of a pyrrolopyridine compound | |
| RU2021110821A (ru) | Применение ингибитора катепсина s против образования противолекарственных антител | |
| US20240415843A1 (en) | Uses of tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors | |
| US10392397B2 (en) | Heterocyclic thiosemicarbazone derivatives and their therapeutical applications | |
| HK40012625B (zh) | 抗her2抗体-药物偶联物和化疗剂的组合,及使用方法 |